BBS4

Across TCGA pan-cancer cohorts, BBS4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BBS4 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BBS4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BBS4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

HNSC, CCRCC, and LSCC are the cancer types where BBS4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.392	0.708	<.001	35	view →
CCRCC	DFS	Median	III,IV	0.960	0.754	.010	19	view →
LSCC	DFS	Quartile	II,III,IV	0.825	1.000	.012	5	view →
LUAD	DFS	Median	All	0.720	0.527	.047	1	view →
PDAC	OS	Median	All	0.973	0.829	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BBS4–HNSC (DFS)

Open the HNSC breakdown →